Burleson & Co’s Quince Therapeutics QNCX Stock Holding History

Burleson & Co’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.82K	Sell	421 -398	-49%	-$66.6K	﹤0.01%	339
2022 Q3	$23K	Buy	819 +75	+10%	+$28.6K	﹤0.01%	241
2022 Q2	$58K	Sell	744 -467	-39%	-$330K	0.01%	177
2022 Q1	$240K	Buy	1,211 +788	+186%	+$1.07M	0.04%	131
2021 Q4	$130K	Sell	423 -775	-65%	-$4.73M	0.02%	163
2021 Q3	$5.36M	Buy	+1,198	New	+$19.1M	0.8%	29
2021 Q2	–	Sell	-223	Closed	-$696K	–	392
2021 Q1	$696K	Buy	+223	New	+$1.6M	0.11%	86
2020 Q4	–	Sell	-34	Closed	-$93K	–	134
2020 Q3	$93K	Buy	+34	New	+$309K	0.02%	131

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Burleson & Co's QNCX Position: Q4 2022 in Review

Burleson & Co reduced its Quince Therapeutics (QNCX) stake by 97% in Q4 2022, selling an estimated $247K and leaving 42 shares worth $5.36K. The position accounts for ﹤0.01% of the portfolio, ranked #302.

Burleson & Co first reported a position in QNCX in Q4 2019 and has held it in 13 quarters since. The position peaked at $12.4M in Q3 2021. 48 funds tracked by Wall St. Rank hold QNCX as of Q4 2022.

Burleson & Co held 42 shares of Quince Therapeutics worth $5.36K as of Q4 2022.
Burleson & Co sold 1,478 Quince Therapeutics shares in Q4 2022, an estimated $247K.
Quince Therapeutics made up ﹤0.01% of Burleson & Co's portfolio in Q4 2022, its #302 holding.
Burleson & Co first reported a position in Quince Therapeutics in Q4 2019 and has held it in 13 quarters since.
Burleson & Co's Quince Therapeutics position peaked at $12.4M in Q3 2021.
48 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.